<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Collegium Pharmaceutical Inc — News on 6ix</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc</link>
<description>Latest news and press releases for Collegium Pharmaceutical Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/collegium-pharmaceutical-inc" rel="self" type="application/rss+xml" />
<item>
<title>Collegium to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmac</description>
</item>
<item>
<title>Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-to-acquire-azstarysr-from-corium-therapeutics-strengthening-position-in-adhd-and-accelerating-growth-trajectory</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-to-acquire-azstarysr-from-corium-therapeutics-strengthening-position-in-adhd-and-accelerating-growth-trajectory</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact</description>
</item>
<item>
<title>Collegium to Present New Real-World Data at PainConnect 2026</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-to-present-new-real-world-data-at-painconnect-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-to-present-new-real-world-data-at-painconnect-2026-8</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring</description>
</item>
<item>
<title>Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/paris-hilton-shares-her-experience-with-jornay-pm-and-launches-new-embrace-your-sparkle-campaign-with-collegium-to-empower-the-adhd-community</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/paris-hilton-shares-her-experience-with-jornay-pm-and-launches-new-embrace-your-sparkle-campaign-with-collegium-to-empower-the-adhd-community</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common</description>
</item>
<item>
<title>Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with</description>
</item>
<item>
<title>Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-report-fourth-quarter-full-130000475</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-report-fourth-quarter-full-130000475</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference th</description>
</item>
<item>
<title>Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-present-four-real-world-data-posters-apsard-2026-annual-conference-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-present-four-real-world-data-posters-apsard-2026-annual-conference-2026-01</guid>
<pubDate>Thu, 15 Jan 2026 05:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations</description>
</item>
<item>
<title>Collegium Provides 2026 Financial Guidance and Business Update</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-provides-2026-financial-guidance-and-business-update-2026-01-08</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-provides-2026-financial-guidance-and-business-update-2026-01-08</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million</description>
</item>
<item>
<title>Collegium Announces the Closing of $980 Million Syndicated Credit Facility</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-announces-closing-980-million-syndicated-credit-facility-2025-12-30</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-announces-closing-980-million-syndicated-credit-facility-2025-12-30</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical,</description>
</item>
<item>
<title>Dyne Therapeutics Appoints Vikram Karnani to Board of Directors</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/dyne-therapeutics-appoints-vikram-karnani-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/dyne-therapeutics-appoints-vikram-karnani-to-board-of-directors</guid>
<pubDate>Tue, 23 Dec 2025 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and hav</description>
</item>
<item>
<title>Collegium to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-participate-upcoming-investor-conferences-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-participate-upcoming-investor-conferences-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the</description>
</item>
<item>
<title>Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-reports-third-quarter-2025-financial-results-raises-2025-guidance-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-reports-third-quarter-2025-financial-results-raises-2025-guidance-2025-11</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew</description>
</item>
<item>
<title>Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/paris-hilton-collaborates-collegium-pharmaceutical-share-her-personal-adhd-journey</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/paris-hilton-collaborates-collegium-pharmaceutical-share-her-personal-adhd-journey</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider</description>
</item>
<item>
<title>Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025</description>
</item>
<item>
<title>Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-announces-poster-presentations-american-academy-child-adolescent-psychiatry</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-announces-poster-presentations-american-academy-child-adolescent-psychiatry</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations</description>
</item>
<item>
<title>Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-celebrate-10-year-anniversary-nasdaq-opening-bell-ringing-2025-10-13</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-celebrate-10-year-anniversary-nasdaq-opening-bell-ringing-2025-10-13</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:</description>
</item>
<item>
<title>Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-present-nine-real-world-data-posters-painweek-2025-annual-meeting-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-present-nine-real-world-data-posters-painweek-2025-annual-meeting-2025-08</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing</description>
</item>
<item>
<title>Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-reports-second-quarter-2025-financial-results-raises-2025-outlook-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-reports-second-quarter-2025-financial-results-raises-2025-outlook-2025-08</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and</description>
</item>
<item>
<title>Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-report-second-quarter-2025-financial-results-august-7-2025-2025-07-24</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-report-second-quarter-2025-financial-results-august-7-2025-2025-07-24</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025</description>
</item>
<item>
<title>Collegium Announces $150 Million Share Repurchase Program</title>
<link>https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-announces-150-million-share-repurchase-program-2025-07-07</link>
<guid isPermaLink="true">https://6ix.com/company/collegium-pharmaceutical-inc/news/collegium-announces-150-million-share-repurchase-program-2025-07-07</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed</description>
</item>
</channel>
</rss>